Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	ILA 156.30	-2.37%	44,618
28/07/26	ILA 160.10	-6.15%	80,169
27/07/26	ILA 170.60	-1.67%	95,233
24/07/26	ILA 173.50	+2.18%	89,117
22/07/26	ILA 169.80	-1.22%	272,019

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 11:55:41 29/07/26 pm AEST			5-day change	1st Jan Change
156.30 ^ILa	-2.37%		-7.95%	-48.00%

27/07	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI

Market Cap	5.47M 0 4.8M 4.47M 4.11M 7.7M 522M 7.83M 52.99M 20.74M 259M 20.52M 20.07M 895M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.47M 0 4.8M 4.47M 4.11M 7.7M 522M 7.83M 52.99M 20.74M 259M 20.52M 20.07M 895M	EV / Sales 2026 *	3.68x	EV / Sales 2027 *	2.1x
Free-Float	82.98%	Yield 2026 *	-	Yield 2027 *	-

27/07	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
11/07	L.I.A. Pure Capital Sends Letter to Evogene	CI
09/07	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
24/06	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
02/06	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
21/05	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/05	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
20/05	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
19/05	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
25/04	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
03/04	Evogene reports receipt of Nasdaq minimum bid price notification	RE

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
19/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
30/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

Evogene Ltd. Stock

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Chart: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Evogene Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

22/07	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
08/07	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
02/06	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
20/05	Evogene : Q1 2026 Consolidated Financial Statements	PU
20/05	Evogene: Q1 Earnings Snapshot	AQ

1 day	-2.37%
1 week	-7.95%
Current month	+22.49%
1 month	+26.15%
3 months	-32.22%
6 months	-52.19%
Current year	-48.00%

1 week	156.2	181
1 month	122.7	194.1
Current year	115.1	410
1 year	115.1	478.7
3 years	115.1	3,954
5 years	115.1	10,430
10 years	115.1	33,500

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/26	Polina Ravzin	Other	Executive/Senior Manager	20,000	0.2294%
18/3/26	Adrian Percy	Other	Director	11,200	0.1285%
18/3/26	Leon Recanati	Other	Director	95,086	1.0907%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	-2.37%	-7.95%	-63.53%	-95.94%	5.47M
LONZA GROUP AG	+1.45%	+6.00%	-2.00%	+12.55%	47.88B
REVOLUTION MEDICINES, INC.	-1.40%	-0.61%	+391.50%	+592.97%	39.09B
BEONE MEDICINES AG	-1.00%	+2.54%	+7.30%	+53.14%	36.75B
IQVIA HOLDINGS INC.	+2.45%	+25.45%	+28.01%	+11.30%	40.55B
CELLTRION, INC.	-0.73%	+3.38%	+4.94%	+41.45%	27.96B
ASCENDIS PHARMA A/S	+0.16%	+1.44%	-	-	16.77B
MEDPACE HOLDINGS, INC.	+1.10%	+7.68%	+26.96%	+124.62%	15.94B
EUROFINS SCIENTIFIC SE	-0.09%	-2.92%	+3.04%	+9.49%	13.55B
ICON PUBLIC LIMITED COMPANY	-0.54%	+7.36%	-3.03%	-28.57%	13.81B
Average	-0.07%	+3.49%	+43.69%	+80.11%	25.23B
Weighted average by Cap.	+0.29%	+5.03%	+72.94%	+123.42%

	2026 *	2027 *
Net sales	1.48M 0 1.3M 1.21M 1.12M 2.09M 142M 2.13M 14.39M 5.63M 70.31M 5.57M 5.45M 243M	2.6M 0 2.28M 2.12M 1.95M 3.66M 248M 3.73M 25.21M 9.87M 123M 9.76M 9.55M 426M
Net income	-16.69M -0 -14.64M -13.64M -12.54M -23.51M -1.59B -23.92M -162M -63.33M -791M -62.65M -61.29M -2.73B	-13.92M -0 -12.21M -11.37M -10.46M -19.61M -1.33B -19.94M -135M -52.81M -659M -52.24M -51.11M -2.28B
Net Debt	-	-